Skip to content
Lower risk Drug recall · FDA · Published November 26, 2025

Somerset Therapeutics Cisatracurium Besylate Injection Recall: Subpotent Product Risk

Somerset Therapeutics recalls 10x10mL Cisatracurium Besylate Injection vials due to subpotent product from stability testing. Affected lots may not be effective for medical use.

🇺🇸 FDA recall #D-0238-2026DrugSomerset Therapeutics ›
Take action

Contact the company

Recalling firmSOMERSET THERAPEUTICS LLC300 Franklin Square Dr · Somerset, NJ 08873-4187
✎ GovInfoNow plain-language explainer

Somerset Therapeutics is recalling certain Cisatracurium Besylate Injection vials because lab tests showed the product is less potent than it should be. This means the medication might not work properly when used as intended. Read more at govinfonow.com/recall/31625-somerset-therapeutics-cisatracurium-besylate-injection-recall-subpotent-product-risk.

Source Summary by GovInfoNow · govinfonow.com/recall/31625-somerset-therapeutics-cisatracurium-besylate-injection-recall-subpotent-product-risk · Updated August 17, 2026 · FDA enforcement record: FDA #D-0238-2026

Cite this page

“Somerset Therapeutics Cisatracurium Besylate Injection Recall: Subpotent Product Risk.” GovInfoNow, updated August 17, 2026. https://govinfonow.com/recall/31625-somerset-therapeutics-cisatracurium-besylate-injection-recall-subpotent-product-risk. Based on FDA recall #D-0238-2026 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0238-2026%22&limit=1).

The FDA announced on Nov. 26, 2025, that Somerset Therapeutics is voluntarily recalling Cisatracurium Besylate Injection USP due to subpotent product risks from out-of-specification assay results. The recall affects 71,310 vials distributed nationwide.

How to tell if you have it

  • Brand: Somerset Therapeutics
  • Product: Cisatracurium Besylate Injection USP, 20 mg/10 mL*, (2 mg/mL), 10 x 10 mL Multiple-dose Vials per carton
  • NDC: 70069-161-01
  • Lot Code: A250043
  • Expiration Date: 06/30/2026

The hazard

The product is subpotent due to out-of-specification assay results observed during long-term stability testing. The FDA classified this as a Class III recall.

Context

GovInfoNow's records show Somerset Therapeutics has issued four other recalls since June 4, 2020. Recent similar recalls include the Dexamethasone Injection Recall on Feb. 4, 2026, and the Atropine Sulfate Ophthalmic Solution Recall on Dec. 16, 2024. Other recent recalls of similar products include the Clinere Carbamide Peroxide Recall (June 25, 2026) and the Daptomycin Injection Recall (Aug. 6, 2026).

How to tell if you have this one

Check for the product name 'Cisatracurium Besylate Injection USP, 20 mg/10 mL', 10 vials per carton, NDC 70069-161-01, and lot number A250043 with expiration date 06/30/2026.

  • Brand
    Somerset Therapeutics
  • Category
    Drug
FDA recall event · 3 products

All 3 products in this recall

FDA lists each product line separately under one recall event. Check your product description, lot or code numbers against each row. Every row shares the hazard and remedy on this page.

  • Classification
    Class III
  • Status
    Ongoing
  • Distribution
    Nationwide in the USA
Recall numberProduct, codes & lotsQuantityNDC
D-0236-2026Cisatracurium Besylate Injection USP, 10 mg/5 mL* (2mg/mL), 10 x 5 mL Single-dose Vials per Carton, Rx Only, Manufactured for: Somerset Therapeutics, LLC, Hollywood, FL 33024, Made in India, Single-dose 5 mL vial NDC 70069-141-01; 10x5 mL single dose vial per Carton NDC 70069-141-10.; Lot#: A240438, Exp Date 1/31/26, A250125, Exp Date 8/31/2652,340 5mL vials70069-141-01, 70069-141-10, 70069-151-01, 70069-151-10
D-0237-2026Cisatracurium Besylate Injection USP, 200mg/20mL*(10mg/mL), 10 x 20 mL Single-dose Vials per Carton, Rx Only, Manufactured for: Somerset Therapeutics, LLC, Hollywood, FL 33024, Made in India, Single dose 20mL vial NDC 70069-151-01; 10 x 20 Single dose vials per Carton, NDC 70069-151-10.; Lot #: A250020, Exp Date 06/30/202628,660 20mL vials70069-141-01, 70069-141-10, 70069-151-01, 70069-151-10
D-0238-2026Cisatracurium Besylate Injection USP, 20 mg/10 mL*,(2 mg/mL), 10 x 10 mL Multiple-dose Vials per carton, Rx Only, Manufactured for: Somerset Therapeutics, LLC, Hollywood, FL 33024, Made in India, 10mL Multiple-dose vial, NDC 70069-161-01; 10x10mL Multiple-dose vials per Carton, NDC 70069-161-01.; Lot#: A250043, EXP Date 06/30/202671,310 10mL vials70069-161-01, 70069-161-10
Based on the official FDA remedy

What to do — step by step

  1. Check Product Details

    Verify the product name, NDC 70069-161-01, and lot number A250043 on the vial packaging.

Where it went and when

Where it was distributed

Distributed nationwide.

Alaska: yesAKMaine: yesMEVermont: yesVTNew Hampshire: yesNHWashington: yesWAIdaho: yesIDMontana: yesMTNorth Dakota: yesNDMinnesota: yesMNIllinois: yesILWisconsin: yesWIMichigan: yesMINew York: yesNYRhode Island: yesRIMassachusetts: yesMAOregon: yesORNevada: yesNVWyoming: yesWYSouth Dakota: yesSDIowa: yesIAIndiana: yesINOhio: yesOHPennsylvania: yesPANew Jersey: yesNJConnecticut: yesCTCalifornia: yesCAUtah: yesUTColorado: yesCONebraska: yesNEMissouri: yesMOKentucky: yesKYWest Virginia: yesWVVirginia: yesVAMaryland: yesMDDelaware: yesDEArizona: yesAZNew Mexico: yesNMKansas: yesKSArkansas: yesARTennessee: yesTNNorth Carolina: yesNCSouth Carolina: yesSCDistrict of Columbia: yesDCOklahoma: yesOKLouisiana: yesLAMississippi: yesMSAlabama: yesALGeorgia: yesGAHawaii: yesHITexas: yesTXFlorida: yesFL

FDA distribution: “Nationwide in the USA” States read from FDA’s own wording; “not listed” means the notice does not name it.

Distributed nationwide.

Recall timeline

FDA published this recall 28 days after the firm started it.

1. Firm started the recall: Nov 26, 202512. FDA classified it Class III: Dec 15, 202523. Published in FDA’s Enforcement Report: Dec 24, 202532025
  1. Firm started the recall
  2. FDA classified it Class III
  3. Published in FDA’s Enforcement Report

Dates from the agency record only; steps without a date are left out.

✎ GovInfoNow

Questions people ask

Is this product safe to use?

The product may be less potent than expected, so it should not be used without confirming effectiveness through testing.

Similar recalls

Latest drug recalls

Keep exploring

Where this comes from

The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.

  • Official source: FDA Recall #D-0238-2026 (November 26, 2025) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0238-2026 to see it in context.
  • Plain-language summary written by qwen3:4b on August 17, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
  • GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.
GovInfoNow is an independent guide. We are not FDA or any government agency. Always confirm details with the official recall.Data: CPSC · FDA · NHTSA · USDA